

Page 1 of 1

| <b>Product Description:</b> | MSD GOLD <sup>™</sup> 96-well Streptavidin SECTOR Plate |  |  |
|-----------------------------|---------------------------------------------------------|--|--|
| <b>Catalog Number:</b>      | L15SA-Series                                            |  |  |
| Lot Number:                 | Z0022208                                                |  |  |
| <b>Expiration Date:</b>     | 31 DEC 2026                                             |  |  |

The above plate lot was tested according to MSD's procedures and passed all specifications. Plates were tested using SULFO-TAG labeled biotinylated IgG (BTI).

## **Titration Results:**

| Metric                                                  | Specification | Result |
|---------------------------------------------------------|---------------|--------|
| 0.300 pmol BTI, Ratio of signal to reference lot signal | 85-115%       | Pass   |
| 0.200 pmol BTI, Ratio of signal to reference lot signal | 85-115%       | Pass   |
| 0.100 pmol BTI, Ratio of signal to reference lot signal | 85-115%       | Pass   |
| Max Background Signal (counts)                          | $\leq 100$    | Pass   |
| Standard Deviation of Background Signal (counts)        | ≤15           | Pass   |

## **Uniformity Results:**

Plates sampled from the above plate lot were tested by adding 0.200 pmol BTI to each well.

| Metric                                       | Specification | Result |
|----------------------------------------------|---------------|--------|
| Average Intraplate CV                        | $\leq 6.0\%$  | Pass   |
| Percentage of plates with $CV \le 8.0\%$     | ≥91.5%        | Pass   |
| Number of plates with Intraplate $CV > 12\%$ | 0 Plates      | Pass   |
| Interplate CV                                | $\leq 8.0\%$  | Pass   |

The above product is intended for Research Use Only. Not for use in Diagnostic Procedures.

|                 | Name          | Function | Signature    | Date        |
|-----------------|---------------|----------|--------------|-------------|
| Review/Approval | Karen Hamilla | Quality  | Kann Hamille | 23 JUL 2024 |